What happened
Zhejiang Hisun Pharmaceutical Co., Ltd. announced that its controlling subsidiary, Zhejiang Hisun Animal Health Products Co., Ltd., received a New Veterinary Drug Registration Certificate from the Ministry of Agriculture and Rural Affairs for a compound product containing fipronil, praziquantel, and moxidectin.
The product, classified as a Category IV veterinary drug, is intended for the prevention and treatment of internal and external parasite infections in cats, including fleas, ticks, heartworm, gastrointestinal nematodes, ear mites, and sarcoptic mange.
The certificate was issued on September 7, 2026, and the product was jointly developed by Hisun Animal Health and two other companies.
Why it matters
This approval supports Hisun's strategic expansion in the veterinary drug sector and could enhance its competitive position in the animal health market.
However, the company noted that the product will not significantly impact its financial performance in the short term, as it still needs to obtain a veterinary drug product approval number before it can be marketed.
Key facts
The certificate number is (2026) New Veterinary Drug Certificate No. 90.
The product is a compound of fipronil, praziquantel, and moxidectin in a spot-on formulation.
It is designed for use in cats to prevent and treat various parasitic infections.
What to watch next
Watch for the company's progress in obtaining the veterinary drug product approval number, which is required before the product can be launched.
Monitor the potential impact of this new product on Hisun's veterinary drug business and market share in the coming quarters.